These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Lack of value of repeat stool testing for Clostridium difficile toxin. Mohan SS; McDermott BP; Parchuri S; Cunha BA Am J Med; 2006 Apr; 119(4):356.e7-8. PubMed ID: 16564786 [TBL] [Abstract][Full Text] [Related]
23. Structural characterization of the cell wall binding domains of Clostridium difficile toxins A and B; evidence that Ca2+ plays a role in toxin A cell surface association. Demarest SJ; Salbato J; Elia M; Zhong J; Morrow T; Holland T; Kline K; Woodnutt G; Kimmel BE; Hansen G J Mol Biol; 2005 Mar; 346(5):1197-206. PubMed ID: 15713474 [TBL] [Abstract][Full Text] [Related]
24. [Comparison of AP-PCR methods, ribotyping (PCR-ribotyping) and pulsed-field electrophoresis (PFGE) for strains of Clostridium difficile producing toxin B and not producing toxin A]. Pituch H; van Belkum A; Obuch-Woszczatyński P; Meisel-Mikołajczyk F; Łuczak M Med Dosw Mikrobiol; 2003; 55(1):53-60. PubMed ID: 12908415 [TBL] [Abstract][Full Text] [Related]
25. Toxicity assessment of Clostridium difficile toxins in rodent models and protection of vaccination. Wang S; Rustandi RR; Lancaster C; Hong LG; Thiriot DS; Xie J; Secore S; Kristopeit A; Wang SC; Heinrichs JH Vaccine; 2016 Mar; 34(10):1319-23. PubMed ID: 26614590 [TBL] [Abstract][Full Text] [Related]
28. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. Kyne L; Warny M; Qamar A; Kelly CP N Engl J Med; 2000 Feb; 342(6):390-7. PubMed ID: 10666429 [TBL] [Abstract][Full Text] [Related]
29. [The frequency of Clostridium difficile toxin in neutropenic and non-neutropenic patients with antibiotic-associated diarrhea and analysis of the risk factors]. Tunçcan OG; Ulutan F; Karakuş R Mikrobiyol Bul; 2008 Oct; 42(4):573-83. PubMed ID: 19149078 [TBL] [Abstract][Full Text] [Related]
30. Physical characterization of clostridium difficile toxins and toxoids: effect of the formaldehyde crosslinking on thermal stability. Salnikova MS; Joshi SB; Rytting JH; Warny M; Middaugh CR J Pharm Sci; 2008 Sep; 97(9):3735-52. PubMed ID: 18257030 [TBL] [Abstract][Full Text] [Related]
31. Immunisation of mares with binding domains of toxins A and B of Clostridium difficile elicits serum and colostral antibodies that block toxin binding. Artiushin S; Timoney JF; Fettinger M; Fallon L; Rathgeber R Equine Vet J; 2013 Jul; 45(4):476-80. PubMed ID: 23206274 [TBL] [Abstract][Full Text] [Related]
32. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection. Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701 [TBL] [Abstract][Full Text] [Related]
33. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Tian JH; Fuhrmann SR; Kluepfel-Stahl S; Carman RJ; Ellingsworth L; Flyer DC Vaccine; 2012 Jun; 30(28):4249-58. PubMed ID: 22537987 [TBL] [Abstract][Full Text] [Related]
34. Antigenicity of amino-acid sequences from Clostridium difficile toxin B. Torres JF; Monath TP J Med Microbiol; 1996 Jun; 44(6):464-74. PubMed ID: 8636964 [TBL] [Abstract][Full Text] [Related]
35. [Clostridium difficile strains not producing Toxin A, but producing Toxin B [toxA(-)tox B(+)]--etiologic agent of antibiotic associated diarrhoea (AAD) in Poland]. Pituch H; Obuch-Woszczatyński P; Meisel-Mikołajczyk F; Łuczak M Med Dosw Mikrobiol; 2002; 54(1):45-53. PubMed ID: 12185683 [TBL] [Abstract][Full Text] [Related]
36. [Evaluation of the immunoenzyme test (Elisa) in detecting Clostiridium difficile toxin A in fecal samples]. Barbut F; Caburet F; Petit JC Ann Biol Clin (Paris); 1992; 50(1):31-6. PubMed ID: 1443788 [TBL] [Abstract][Full Text] [Related]
37. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile. Drudy D; Harnedy N; Fanning S; Hannan M; Kyne L Infect Control Hosp Epidemiol; 2007 Aug; 28(8):932-40. PubMed ID: 17620240 [TBL] [Abstract][Full Text] [Related]
38. Phosphorylation of cellular proteins in response to treatment with Clostridium difficile toxin B and Clostridium sordellii toxin L. Ciesielski-Treska J; Ulrich G; Baldacini O; Monteil H; Aunis D Eur J Cell Biol; 1991 Oct; 56(1):68-78. PubMed ID: 1724754 [TBL] [Abstract][Full Text] [Related]
39. Specific detection of Clostridium difficile toxin A gene sequences in clinical isolates. Tang YJ; Gumerlock PH; Weiss JB; Silva J Mol Cell Probes; 1994 Dec; 8(6):463-7. PubMed ID: 7700267 [TBL] [Abstract][Full Text] [Related]
40. Clostridium difficile in adult patients with nosocomial diarrhea in a Costa Rican hospital. Zumbado-Salas R; Gamboa-Coronado Mdel M; Rodríguez-Cavallini E; Chaves-Olarte E Am J Trop Med Hyg; 2008 Aug; 79(2):164-5. PubMed ID: 18689617 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]